

<p>Science & Technology</p>	<p>Strong R&D DNA cultivated over years of operation as a drug discovery-oriented company</p> <ul style="list-style-type: none"> • Incorporated as drug discovery-oriented companies originating from Japan <ul style="list-style-type: none"> ▶ Adrenaline ▶ Salvarsan ▶ Orizantin • Creation and cultivation of leading pharmaceuticals in Japan <ul style="list-style-type: none"> ▶ Ticlopidine ▶ Loxoprofen • Research capabilities for creating innovative pharmaceuticals globally <ul style="list-style-type: none"> ▶ Pravastatin ▶ Levofloxacin • Development capabilities contributing to success in large-scale global clinical trials <ul style="list-style-type: none"> ▶ Olmesartan ▶ Prasugrel ▶ Edoxaban 	<p>Superior pharmaceutical technologies for creating innovative pharmaceuticals</p> <ul style="list-style-type: none"> • Powerful research engines <ul style="list-style-type: none"> ▶ Research labs in Japan combining chemistry and biology expertise ▶ Drug discovery platform in U.S. subsidiary enabling efficient candidate identification • Proprietary ADC technologies <ul style="list-style-type: none"> DS-8201 and following projects in ADC franchise • Diverse modality technologies <ul style="list-style-type: none"> ▶ Nucleic acid drugs ▶ Oncolytic virus ▶ Cell therapies <p>Strong ties with leading-edge academic institutions (open innovation activities)</p> <ul style="list-style-type: none"> • National Cancer Center Japan • Dana-Farber Cancer Institute • University of California, San Francisco • Max Planck Innovation and Lead Discovery Center
<p>Global Organization & Talent</p>	<p>Global management system uniting intellects from around the world</p> <ul style="list-style-type: none"> • Global Management Committee facilitating swift and accurate decision-making • Execution of global matrix management comprised of regional business units and functional units • Global R&D structure enabling swift decision-making • Dynamic global organization for responding promptly to operating environment changes 	<p>Robust, global well of talent</p> <ul style="list-style-type: none"> • Proactive employment of global talents from around the world • Human resources development programs taking advantage of global experience
<p>Presence in Japan</p>	<p>No. 1 in terms of pharmaceutical revenue in Japan</p> <ul style="list-style-type: none"> • Extensive product lineup • High-quality in-licensed products • Strong cooperative relationship with wholesalers • Evaluation as No. 1 in terms of inquiry response <p>MRs* ranked No. 1 in Japan</p> <ul style="list-style-type: none"> • MRs ranked No. 1 by physicians for 5 consecutive years • Reputation for highest level of integrity in the industry • Comprehensive training programs (all MRs passed certificate test for 7 consecutive years) <p><small>* Medical Representatives</small></p>	<p>Four businesses responding to diverse medical needs</p> <ul style="list-style-type: none"> • Innovative pharmaceuticals business • Generic business • Vaccine business • OTC related business

サイエンスが進歩し続けるのは、
考え続ける人がいるから。
わかったこと。わからないこと。
その果てなき積み重ねで、答えに近づいていく。
がんや血栓の治療薬も、例外ではありません。
第一三共が積み重ねてきた知恵に、
新しい切り口を日々加えていく。

そうして生まれるイノベーションの先に、
希望という名のゴールがあると信じて。

イノベーションに情熱を。
ひとに思いやりを。

Daiichi-Sankyo
第一三共株式会社

The above is an advertisement for Daiichi Sankyo in Japan. This advertisement symbolizes our desire to utilize the scientific and technological strength cultivated over our long history, one of Daiichi Sankyo's strengths, to deliver new treatments that will give hope to patients and their families. We stand committed to fulfilling our corporate mission: "To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs."